ECSP18091065A - Ésteres de oxaborol y sus usos - Google Patents
Ésteres de oxaborol y sus usosInfo
- Publication number
- ECSP18091065A ECSP18091065A ECSENADI201891065A ECDI201891065A ECSP18091065A EC SP18091065 A ECSP18091065 A EC SP18091065A EC SENADI201891065 A ECSENADI201891065 A EC SENADI201891065A EC DI201891065 A ECDI201891065 A EC DI201891065A EC SP18091065 A ECSP18091065 A EC SP18091065A
- Authority
- EC
- Ecuador
- Prior art keywords
- oxaborol
- esters
- compositions
- useful
- provides
- Prior art date
Links
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical class O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 title 1
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 1
- 208000024699 Chagas disease Diseases 0.000 abstract 1
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 oxaborol ester compounds Chemical class 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 201000002311 trypanosomiasis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona compuestos de éster de oxaborol y composiciones de los mismos, que son útiles para tratar enfermedades relacionadas con parásitos tales como la enfermedad de Chagas y la Tripanosomiasis Animal africana.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662335565P | 2016-05-12 | 2016-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP18091065A true ECSP18091065A (es) | 2019-07-31 |
Family
ID=58699201
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201891065A ECSP18091065A (es) | 2016-05-12 | 2018-12-11 | Ésteres de oxaborol y sus usos |
ECSENADI201926702A ECSP19026702A (es) | 2016-05-12 | 2019-04-12 | Compuestos novedosos para el tratamiento de enfermedades parasitarias |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201926702A ECSP19026702A (es) | 2016-05-12 | 2019-04-12 | Compuestos novedosos para el tratamiento de enfermedades parasitarias |
Country Status (32)
Country | Link |
---|---|
US (4) | US10562921B2 (es) |
EP (2) | EP3455227A1 (es) |
JP (2) | JP6715957B2 (es) |
KR (2) | KR102231489B1 (es) |
CN (2) | CN109153688A (es) |
AR (2) | AR108450A1 (es) |
AU (2) | AU2017263785B2 (es) |
BR (2) | BR122018076188A2 (es) |
CA (1) | CA3023490C (es) |
CL (2) | CL2018003187A1 (es) |
CO (1) | CO2018012077A2 (es) |
CR (2) | CR20180502A (es) |
DK (1) | DK3578562T3 (es) |
EA (2) | EA034415B1 (es) |
EC (2) | ECSP18091065A (es) |
ES (1) | ES2882782T3 (es) |
HK (1) | HK1258717A1 (es) |
HU (1) | HUE056320T2 (es) |
IL (2) | IL262453A (es) |
MA (1) | MA44968A (es) |
MX (2) | MX2018013743A (es) |
NI (2) | NI201801172A (es) |
NZ (1) | NZ746906A (es) |
PE (2) | PE20191077A1 (es) |
PT (1) | PT3578562T (es) |
SG (1) | SG11201809237RA (es) |
TN (2) | TN2019000106A1 (es) |
TW (1) | TWI629279B (es) |
UA (2) | UA121354C2 (es) |
UY (2) | UY37236A (es) |
WO (1) | WO2017195069A1 (es) |
ZA (1) | ZA201901168B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
TW201735792A (zh) | 2016-03-07 | 2017-10-16 | 農業保鮮股份有限公司 | 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法 |
KR102231489B1 (ko) * | 2016-05-12 | 2021-03-23 | 아나코르 파마슈티칼스 인코포레이티드 | 기생충 질병을 치료하기 위한 신규 화합물 |
WO2019108982A1 (en) | 2017-11-30 | 2019-06-06 | Boragen, Inc. | Benzoxaborole compounds and formulations thereof |
JP2020180170A (ja) * | 2019-04-23 | 2020-11-05 | 東ソー株式会社 | ハロゲン含有ポリエーテルポリオール組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
US9493489B2 (en) * | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
WO2010045505A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
US9440994B2 (en) | 2009-08-14 | 2016-09-13 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules as antiprotozoal agents |
PL2673281T3 (pl) | 2011-02-07 | 2016-10-31 | Zawierające bor wielozasadowe inhibitory pomp usuwających substancje z komórek bakteryjnych oraz ich zastosowania terapeutyczne | |
RU2604496C2 (ru) * | 2011-10-07 | 2016-12-10 | Зингента Партисипейшнс Аг | Способ защиты полезных растений или растительного материала для размножения |
AR088669A1 (es) | 2011-11-21 | 2014-06-25 | Lilly Co Eli | Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos |
US8669207B1 (en) | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
WO2015013318A1 (en) | 2013-07-22 | 2015-01-29 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
HRP20220384T1 (hr) | 2013-08-09 | 2022-07-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Triciklički benzoksaborol spojevi i njihove uporabe |
EP3086645A1 (en) * | 2013-12-23 | 2016-11-02 | Syngenta Participations AG | Benzoxaborole fungicides |
EP3337809A1 (en) * | 2015-08-17 | 2018-06-27 | Syngenta Participations Ag | 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides |
KR102231489B1 (ko) * | 2016-05-12 | 2021-03-23 | 아나코르 파마슈티칼스 인코포레이티드 | 기생충 질병을 치료하기 위한 신규 화합물 |
-
2017
- 2017-05-01 KR KR1020187035855A patent/KR102231489B1/ko active IP Right Grant
- 2017-05-01 PE PE2019000887A patent/PE20191077A1/es unknown
- 2017-05-01 CR CR20180502A patent/CR20180502A/es unknown
- 2017-05-01 BR BR122018076188A patent/BR122018076188A2/pt not_active Application Discontinuation
- 2017-05-01 HU HUE19180969A patent/HUE056320T2/hu unknown
- 2017-05-01 EA EA201892203A patent/EA034415B1/ru unknown
- 2017-05-01 EP EP17722886.3A patent/EP3455227A1/en not_active Withdrawn
- 2017-05-01 SG SG11201809237RA patent/SG11201809237RA/en unknown
- 2017-05-01 CN CN201780029103.2A patent/CN109153688A/zh active Pending
- 2017-05-01 CN CN201811522724.7A patent/CN109503637B/zh active Active
- 2017-05-01 MA MA044968A patent/MA44968A/fr unknown
- 2017-05-01 WO PCT/IB2017/052522 patent/WO2017195069A1/en active Application Filing
- 2017-05-01 TN TNP/2019/000106A patent/TN2019000106A1/en unknown
- 2017-05-01 AU AU2017263785A patent/AU2017263785B2/en not_active Ceased
- 2017-05-01 PT PT191809698T patent/PT3578562T/pt unknown
- 2017-05-01 EP EP19180969.8A patent/EP3578562B1/en active Active
- 2017-05-01 MX MX2018013743A patent/MX2018013743A/es unknown
- 2017-05-01 CR CR20180560A patent/CR20180560A/es unknown
- 2017-05-01 ES ES19180969T patent/ES2882782T3/es active Active
- 2017-05-01 CA CA3023490A patent/CA3023490C/en active Active
- 2017-05-01 JP JP2018559924A patent/JP6715957B2/ja not_active Expired - Fee Related
- 2017-05-01 UA UAA201811418A patent/UA121354C2/uk unknown
- 2017-05-01 BR BR122023022427-2A patent/BR122023022427A2/pt not_active Application Discontinuation
- 2017-05-01 EA EA201892475A patent/EA036661B1/ru not_active IP Right Cessation
- 2017-05-01 NZ NZ746906A patent/NZ746906A/en not_active IP Right Cessation
- 2017-05-01 TN TNP/2018/000351A patent/TN2018000351A1/en unknown
- 2017-05-01 DK DK19180969.8T patent/DK3578562T3/da active
- 2017-05-01 UA UAA201810456A patent/UA120999C2/uk unknown
- 2017-05-01 KR KR1020187035848A patent/KR102243775B1/ko active IP Right Grant
- 2017-05-01 PE PE2018002055A patent/PE20190119A1/es unknown
- 2017-05-09 TW TW106115364A patent/TWI629279B/zh not_active IP Right Cessation
- 2017-05-09 US US15/590,159 patent/US10562921B2/en active Active
- 2017-05-10 UY UY0001037236A patent/UY37236A/es unknown
- 2017-05-11 AR ARP170101250A patent/AR108450A1/es unknown
-
2018
- 2018-10-17 IL IL262453A patent/IL262453A/en unknown
- 2018-11-08 CO CONC2018/0012077A patent/CO2018012077A2/es unknown
- 2018-11-09 CL CL2018003187A patent/CL2018003187A1/es unknown
- 2018-11-09 NI NI2018001172A patent/NI201801172A/es unknown
- 2018-11-09 MX MX2018015410A patent/MX2018015410A/es unknown
- 2018-11-09 NI NI2018001171A patent/NI201801171A/es unknown
- 2018-11-16 AU AU2018264116A patent/AU2018264116B2/en not_active Ceased
- 2018-11-20 IL IL263161A patent/IL263161B/en unknown
- 2018-11-22 UY UY0001037980A patent/UY37980A/es unknown
- 2018-11-23 AR ARP180103435A patent/AR113543A2/es unknown
- 2018-11-27 CL CL2018003377A patent/CL2018003377A1/es unknown
- 2018-12-11 EC ECSENADI201891065A patent/ECSP18091065A/es unknown
-
2019
- 2019-01-22 HK HK19101118.4A patent/HK1258717A1/zh unknown
- 2019-01-24 JP JP2019009932A patent/JP6715966B2/ja not_active Expired - Fee Related
- 2019-02-25 ZA ZA2019/01168A patent/ZA201901168B/en unknown
- 2019-04-12 EC ECSENADI201926702A patent/ECSP19026702A/es unknown
- 2019-09-24 US US16/580,676 patent/US10882872B2/en active Active
-
2020
- 2020-12-01 US US17/108,066 patent/US11578087B2/en active Active
-
2022
- 2022-12-22 US US18/145,315 patent/US20230132298A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP18091065A (es) | Ésteres de oxaborol y sus usos | |
CO2017011484A2 (es) | Inhibidores de bromodominio | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2017003389A1 (es) | Composiciones de pienso para animales y usos de las mismas. | |
UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
CO2017004736A2 (es) | Péptidos macrociclicos útiles como inmunomoduladores | |
SV2016005311A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
DOP2017000298A (es) | Reguladores de nrf2 | |
CL2017003055A1 (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares. | |
CR20160229A (es) | Inhibidires de bromodominio | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
CL2017001046A1 (es) | Inhibidoes del bromodominio | |
GT201700188A (es) | Anticuerpos contra tau y sus usos | |
DOP2016000248A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
ECSP18014798A (es) | Inhibidores de ezh2 | |
DOP2018000219A (es) | Anticuerpos anti-factor bb del complemento y usos de estos | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
AR109376A1 (es) | FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA | |
CO2019012475A2 (es) | Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo | |
CL2016002779A1 (es) | Composición para el cuidado de la piel | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
UY36688A (es) | Compuestos de imidazotriazina |